PFE Jun 2024 50.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

2.5800

-0.0400

(-1.53%)

As of 09:30AM EST. Market open.

Zacks
Deciphera's (DCPH) Q4 Earnings Miss, Qinlock Drives Revenues
Deciphera (DCPH) reports a wider-than-expected loss per share for the fourth quarter of 2022, while revenues driven by Qinlock sales, beat estimates.
Zacks
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Motley Fool
This Healthcare Giant Expects Revenue to Crash More Than 30% This Year
Last year was a stellar one for Pfizer (NYSE: PFE). In January, Pfizer announced not only its latest earnings results but also a forecast for 2023, which tells investors what they already knew was inevitable: a sharp decline in sales is coming. A decline in revenue isn't a shock given that concerns surrounding COVID appear to be fading, but the reason for the soft numbers isn't entirely due to demand.